Related Experiment Video
Updated: Jan 9, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Efficacy of Tofacitinib in Alopecia Areata - Lucky Punch or Robust Treatment Option?
Merian Ranjbaryan1, Peter Weisenseel1, Syrus Alexander Karsai1,2
1Department of Dermatology, Dermatologikum Hamburg, Hamburg, Germany.
Abstract:
This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future.
Insights
This case study highlights a patient with alopecia areata who found success with tofacitinib after treatments with Baricitinib and Abrocitinib failed. Tofacitinib may be a future treatment option for alopecia areata.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Alopecia areata is an autoimmune condition causing hair loss.
- Janus kinase (JAK) inhibitors are emerging treatments for alopecia areata.
- Previous JAK inhibitors (Baricitinib, Abrocitinib) were ineffective for this patient.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

